Favorable Japan Environment Nurtures Daiichi/CTL Cell Therapy Deal
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.